Author

A. L. Coelho

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cell Biology· 2 Pharmacology & Toxicology· 2 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Research Focus:cell type annotation· 4 Organism:human· 4 Assay:bulk RNA-seq· 3 Research Focus:differential expression· 2 Assay:proteomics· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:development & morphogenesis· 1

Frequent Co-Authors

C. M. Hogaboam· 5 shared B. Creyns· 2 shared B. MacKenzie· 2 shared A. Beppu· 1 shared A. Guenther· 1 shared A. Mikels-Vigdal· 1 shared B. R. Stripp· 1 shared B. Windsor· 1 shared

Activity by Year

2019-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersPharmacology & Toxicology

C. M. Hogaboam

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Pre-clinical proof-of-concept of anti-fibrotic activity of caveolin-1 scaffolding domain peptide LTI-03 in ex vivo precision cut lung slices from patients with Idiopathic Pulmonary Fibrosis

B. MacKenzie, P. Mahavadi, Y. A. P. Jannini-Sa, B. Creyns, A. L. Coelho, M. Espindola, C. Ruppert, K. Hoetzenecker, C. M. Hogaboam, A. Guenther

This study evaluates the anti-fibrotic effects of LTI-03 in IPF patient-derived precision cut lung slices, showing dose-dependent reduction of fibrotic markers.

bioRxiv · Apr 24, 2024 · PreprintPharmacology & Toxicology

Caveolin scaffolding domain (CSD) peptide LTI-2355 modulates the phagocytic and synthetic activity of lung derived myeloid cells in Idiopathic Pulmonary Fibrosis (IPF) and Post-acute sequelae of COVID-fibrosis (PASC-F)

B. Creyns, B. MacKenzie, Y. Sa, A. L. Coelho, D. Christensen, T. Parimon, B. Windsor, C. M. Hogaboam

This study shows that the CSD peptide LTI-2355 improves phagocytic and reduces pro-inflammatory activity in myeloid cells from IPF and PASC-F patients.

bioRxiv · Dec 1, 2023Immunology

Effects of anti-fibrotic standard of care drugs on senescent human lung fibroblasts

S. Garcia, M. Hohmann, A. L. Coelho, C. M. Hogaboam

This study examines the effects of nintedanib and pirfenidone on senescent lung fibroblasts, finding they do not induce apoptosis and may increase fibrotic markers.

bioRxiv · May 6, 2022 · PreprintPharmacology & Toxicology

Epithelial Plasticity and Innate Immune Activation Promote Lung Tissue Remodeling following Respiratory Viral Infection.

A. Beppu, J. Zhao, C. Yao, G. Carraro, E. Israely, A. L. Coelho, C. M. Hogaboam, W. C. Parks, J. K. Kolls, B. R. Stripp

This study shows that epithelial plasticity and innate immune activation contribute to lung tissue remodeling after viral infection, protecting against mortality but causing long-term lung dysfunction.

bioRxiv · Sep 22, 2021Cell Biology

Targeting Lysyl oxidase-like 2 in Idiopathic Pulmonary Fibrosis

M. S. Espindola, D. M. Habiel, A. L. Coelho, A. Mikels-Vigdal, C. M. Hogaboam

This study examines the role of LOXL2 in IPF using Simtuzumab, finding it enhances myofibroblast differentiation and fibrosis but shows no therapeutic efficacy.

bioRxiv · Oct 22, 2019Cell Biology